Trials / Conditions / Transfusional Iron Overload

Transfusional Iron Overload

13 registered clinical trials studyying Transfusional Iron Overload.

Status	Trial	Sponsor	Phase
Withdrawn	Treatment of Iron Overload Requiring Chelation Therapy NCT01927913	Shire	Phase 2
Terminated	Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study NCT01326845	Novartis Pharmaceuticals	Phase 4
Terminated	Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iro NCT01363908	Shire	Phase 2
Completed	High-Tc Susceptometer to Monitor Transfusional Iron Overload NCT01241357	Columbia University	—
Completed	Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload NCT01186419	Shire	Phase 2
Completed	Active Drug Surveillance Program of Ferriprox Use NCT01838291	ApoPharma	—
Completed	Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overlo NCT01039636	FerroKin BioSciences, Inc.	Phase 1
Completed	Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Ind NCT00673608	Novartis	Phase 4
Completed	Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload NCT00600938	Novartis Pharmaceuticals	Phase 2
Completed	Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transf NCT00560820	Novartis Pharmaceuticals	Phase 1
Completed	A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Majo NCT00390858	Novartis Pharmaceuticals	Phase 2
Completed	A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Tr NCT01044186	Novartis Pharmaceuticals	Phase 2
Completed	Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload NCT00379483	Novartis Pharmaceuticals	Phase 2